Author's response to reviews

Title: Safety, Pharmacokinetics and Pharmacodynamics of Remogliflozin Etabonate, a Novel SGLT2 Inhibitor, and Metformin when Co-administered in Subjects with Type 2 Diabetes Mellitus

Authors:

Elizabeth K Hussey (elizabeth.k.hussey@gsk.com)
Anita Kapur (anita.x.kapur@gsk.com)
Robin L O'Connor-Semmes (robin.l.o'connor-semmes@gsk.com)
Wenli Tao (wenli.x.tao@gsk.com)
Bryan M Rafferty (bryan.m.rafferty@gsk.com)
Joseph W Polli (joseph.w.polli@gsk.com)
Chuck D James (Chuck.james@labcorp.com)
Robert L Dobbins (robert.l.dobbins@gsk.com)

Version: 6 Date: 16 April 2013

Author's response to reviews:

Editorial changes have been incorporated.